The Use of Lenalidomide in the Treatment of Multiple Myeloma

Česká verzia

Authors: M. Holánek; R. Hájek
Authors place of work: Interní hematoonkologická klinika, FN Brno
Published in the journal: Klin Onkol 2010; 23(2): 67-72
Category: Reviews

Summary

Lenalidomide is a promising new drug in the treatment of patients with multiple myeloma. The analogue of thalidomide was created with the intention of improving the anticancer activity, its immunomodulatory properties as well as reducing the toxicity of the preparation. The mechanism of antitumor action of the preparation appears to be the effect on cells, tumour microenvironment and in particular the regulation of cytokinine production. Performed clinical studies Phase I and II have shown efficacy in patients with relapsed multiple myeloma. Subsequently, large randomized trials demonstrated the benefit of combined therapy in relapsed/refractory multiple myeloma patients with a combination of lenalidomide plus dexamethasone compared with dexamethasone treatment alone. Patients treated with a combination of lenalidomide and dexamethasone had significantly higher therapeutic response and overall survival than patients treated with dexamethasone alone. Profound toxicity seems to be the myelosuppressive effect of lenalidomide. The work gives a summary of the information available on lenalidomide in the treatment of multiple myeloma.

Key words:
lenalidomide – thalidomide – multiple myeloma – autologous peripheral blood stem cell transplantation

Zdroje

1. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4(4): 314– 322.

2. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341(21): 1565– 1571.

3. Knight R. IMiDs: A novel class of immunomodulators. Semin Oncol 2005; 32 (4 Suppl 5): S24– S30.

4. Marriot JB, Dredge K, Dalgleish AG. Thalidomide derived immunomodulatory drugs (IMids) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metab Disord 2003; 3(3): 181– 186.

5. Anderson KC. Lenalidomide and Thalidomide: Mechanisms of action – similarities and differences. Semin Hematom 2005; 42 (4 Suppl 4): S3– S8.

5. Corral LG, Haslett PA, Müller GW et al. Differential cytokine modulation and T‑ cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF‑alpha. J Immunol 1999; 163(1): 380– 386.

6. Zeldis JB, Williams BA, Thomas SD et al. S.T.E.P.S.: a comprehensive program for controling and monitoring access to thalidomide. Clin Ther 1999; 21(2): 319– 330.

7. Richardson PG, Schlossman RL, Keller E et al. Immunomodulatory drug CC‑ 5013 overcomes drugs resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100(9): 3063– 3067.

8. Richardson PG, Blood E, Mitsiades CS et al. A randomized phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108(10): 3458– 3464.

9. Richardson PG, Barlogie B, Berenson J et al. SUMMIT Investigators. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106(9): 2977– 2981.

10. Weber DM, Chen C, Niesvizky R et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357(21): 2133– 2142.

11. Baz R, Walker E, Karam MA et al. Lenalidomide and pegylated liposomal doxorubicin‑based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17(12): 1766– 1771.

12. Morgan GJ, Schey SA, Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137(3): 268– 269.

13. Richardson PG, Jagannath S, Avigan D et al. Lenalidomide plus Bortezomib (Rev‑ Vel) in relapsed/ refractory multile myeloma: Final results of a multicenter phase I trial. Proc Am Soc Hematol 2006 (abstr 405).

14. Lacy MQ, Gertz MA, Dispenzieri A et al. Long‑term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82(10): 1179– 1184.

15. Niesvizky R, Jayabalan DS, Christos PJ at al. BiRD (Biaxin [clarithromycin]/ Revlimid [lenalidomide]/ dexamethasone) combination therapy results in high complete‑ and overall‑response rates in treatment‑ naive symptomatic multiple myeloma. Blood 2008; 111(3): 1101– 1109.

16. Palumbo A, Falco P, Corradini P et al. GIMEMA‑ Italian Multiple Myeloma Network. Melphalan, Prednisone and Lenalidomide treatment for newly diagnose myeloma: A report from GIMEMA‑ Italian Multiple Myeloma Network. J Clin Oncol 2007; 25(28): 4459– 4465.

17. Palumbo A, Dimopoulos MA, Delforge M et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Program and abstracts of the 51st American Society of Hematology Annual Meeting and Exposition. Louisiana 2009: Abstract 613.

18. Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 2007; 8(4): 497– 509.

19. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC‑ 5013 overcomes drugs resistence and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100(9): 3063– 3067.

20. Weber DM, Spenser A, Wang M et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function. J Clin Oncol 2008; 26: Abstr. 8542.

21. Gertz MA, Kumar SK, Lacy MQ et al. Comparison of high‑dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43(8): 619– 25.

22. Kumar S, Lacy MQ, Dispenzieri A et al. Stem cell mobilization folowing initial therapy with lenalidomide and dexamethasone in patiens with newly diagnosed multiple myeloma. Blood 2008; 112: 3467 (ASH Annual Meeting Abstracts).

23. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357(21): 2123– 2132.